Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

Annals of Oncology : Official Journal of the European Society for Medical Oncology
P F FerrucciC Martinoli

Abstract

Clinical responses to ipilimumab are variable in terms of onset, magnitude and duration. Upfront identification of patients who are more likely or unlikely to benefit from treatment is a major need. Prospectively collected data from 720 advanced melanoma patients treated with ipilimumab 3 mg/kg within the Italian expanded access program were analyzed. The derived neutrophil-to-lymphocyte ratio (dNLR) was calculated from baseline peripheral blood cell counts, and receiver operating characteristic curve was used to evaluate the best cutoff for this marker. Patients were stratified according to dichotomized baseline absolute neutrophil counts (ANC), dNLR and their combination. The prognostic values of ANC and dNLR for survival were assessed using multivariate Cox proportional hazard models. A subgroup analysis including LDH in the models was also carried out. The median follow-up was 16.5 months. The optimal cutoff for dNLR was 3. Baseline ANC and dNLR were significantly associated with the outcome of ipilimumab-treated melanoma patients, in terms of disease progression and death (P < 0.0001 for all). Furthermore, for each elevated variable, prognosis worsened. Patients with both ANC ≥ 7500 and dNLR ≥ 3 had a significantly and ind...Continue Reading

References

Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles M BalchVernon K Sondak
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Jul 26, 2012·British Journal of Cancer·M J ProctorS J Clarke
Feb 14, 2013·Seminars in Cancer Biology·Frede Donskov
Mar 13, 2014·Cancer Immunology, Immunotherapy : CII·Sander KeldermanChristian U Blank
May 31, 2014·Journal of the National Cancer Institute·Arnoud J TempletonEitan Amir
Jul 22, 2014·Melanoma Research·Alfonso BerrocalUNKNOWN Spanish Melanoma Group
Oct 5, 2014·The Lancet Oncology·Connie I DiakosStephen J Clarke
Dec 30, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M Di GiacomoM Maio
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk SchadendorfJedd D Wolchok
Feb 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michele MaioJedd D Wolchok
Aug 1, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S ValpioneV Chiarion-Sileni

❮ Previous
Next ❯

Citations

Jun 3, 2016·International Journal of Cancer. Journal International Du Cancer·Sara GandiniChiara Martinoli
Jul 13, 2016·Expert Review of Anticancer Therapy·Pol Specenier
Sep 19, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Melvin Lee Kiang ChuaTerence Wee Kiat Tan
Sep 7, 2016·Vaccines·Saskia J A M SantegoetsSjoerd H van der Burg
May 25, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephanie L GoffSteven A Rosenberg
Jan 27, 2017·Melanoma Research·Leonardo S Lino-SilvaCésar Zepeda-Najar
Jul 14, 2017·International Journal of Technology Assessment in Health Care·Alberto RussiAngelo Claudio Palozzo
Jun 18, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yanjuan XiongXiubao Ren
Feb 8, 2018·Molecular Diagnosis & Therapy·Anna EisensteinRhoda M Alani
Sep 8, 2018·Journal of Cellular Physiology·Fatemeh K DermaniRezvan Najafi
Oct 5, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D PlanchardUNKNOWN ESMO Guidelines Committee
Sep 28, 2018·The Journal of Clinical Investigation·Veronica HuberLicia Rivoltini
Jan 5, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K M HeinhuisJ H M Schellens
May 14, 2019·Expert Review of Molecular Diagnostics·Ke MaYuyang Zhang
Apr 20, 2019·Expert Opinion on Biological Therapy·Joseph A PintoChristian C Rolfo
Aug 25, 2019·Cancers·Yoshitaro ShindoHiroaki Nagano
Jun 5, 2019·Nature Reviews. Clinical Oncology·Merav E Shaul, Zvi G Fridlender
Aug 31, 2019·Expert Review of Molecular Diagnostics·Ernest Y Lee, Rajan P Kulkarni
Nov 17, 2019·International Journal of Molecular Sciences·Cristina Maria FaillaStefania D'Atri
Jan 31, 2020·Expert Review of Anticancer Therapy·Caroline A Nebhan, Douglas B Johnson
Nov 23, 2019·European Journal of Nuclear Medicine and Molecular Imaging·Romain-David SebanBenjamin Besse
Apr 3, 2020·Journal for Immunotherapy of Cancer·Luca MazzarellaGiuseppe Curigliano
Mar 20, 2018·Oncotarget·Riccardo MarconciniUNKNOWN Italian Melanoma Intergroup (IMI)
Feb 29, 2020·The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutica·Jose C BenitezLaura Mezquita

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.